Genetic Technologies Limited

Equities

GTG

AU000000GTG7

Healthcare Facilities & Services

Market Closed - Australian S.E. Other stock markets 01:37:35 2024-05-13 am EDT			5-day change	1st Jan Change
0.135 ^AUD	+12.50%		+12.50%	0.00%

May. 06	Genetic Technologies Limited Announces Execution of Strategic Joint Sales & Marketing Agreement with Wellworks for You Inc	CI
May. 06	Genetic Technologies Signs Sales, Marketing Deal with Wellworks for You	MT

Genetic Technologies Limited Provides Revenue Guidance for the Quarter Ending December 2021

October 04, 2021 at 08:00 am EDT

Genetic Technologies Limited provided revenue guidance for the quarter ending December 2021. For the quarter ending December 2021 company expects revenue growth will continue to show a material uplift with the Company scheduled to release its Multi-Test product at the end of the calendar year.

Latest news about Genetic Technologies Limited

Genetic Technologies Limited Announces Execution of Strategic Joint Sales & Marketing Agreement with Wellworks for You Inc	May. 06	CI
Genetic Technologies Signs Sales, Marketing Deal with Wellworks for You	May. 05	MT
Genetic Technologies Raising $2 Million via ADS Offering	Apr. 18	MT
Top Midday Decliners	Apr. 18	MT
Genetic Technologies Agrees to $2 Million Equity Offering	Apr. 18	MT
Genetic Technologies Limited Establishes Precision Oncology Division	Apr. 17	CI
Genetic Technologies Launches GeneType Precision Oncology Brand, Diagnostic Tests	Apr. 16	MT
Genetic Technologies Limited Establishes Clinical Implementation Study with Breast Screen Centres Across New York, Miami and Houston	Apr. 11	CI
Genetic Technologies to Conduct Breast Cancer Integration Study in US	Apr. 10	MT
Genetic Technologies Secures Short-Term Loan from Radium Capital	Mar. 25	MT
Genetic Technologies Limited Announces the Appointment of Kathryn Andrews as Chief Financial Officer	Mar. 25	CI
Genetic Technologies Limited Announces the Appointment of Kathryn Andrews as Company Secretary	Mar. 25	CI
Genetic Technologies Limited to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare	Mar. 25	CI
Genetic Technologies Appoints CFO	Mar. 25	MT
Genetic Technologies Developing 'Most Advanced' Risk-Assessment Test for Serious Diseases; Shares Rise	Mar. 22	MT
Genetic Technologies to Work on Advanced Comprehensive Risk Test; Shares Jump 18%	Mar. 21	MT
Genetic Technologies to Launch US Advertising Campaign for Genome-Based Risk Assessment Test; Shares Surge 21%	Feb. 28	MT
Genetic Technologies Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 23	CI
Genetic Technologies Limited Announces Resignation of Nick Burrows as an Independent Non-Executive Director	Feb. 15	CI
Genetic Technologies Reports AU$3.6 Million in Q4 Cash Receipts	Jan. 31	MT
Genetic Technologies' CFO and Company Secretary Resigns; Shares Rise 3%	Jan. 07	MT
Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Chief Financial Officer	Jan. 07	CI
Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Company Secretary	Jan. 07	CI
Genetic Technologies Files $75 Million Mixed Shelf	Dec. 21	MT
Top Premarket Decliners	Dec. 18	MT

Chart Genetic Technologies Limited

Duration

Period

More charts

Company Profile

Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor

Sector

Healthcare Facilities & Services

Calendar

2024-08-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
GENETIC TECHNOLOGIES LIMITED	0.00%	10.48M
HCA HEALTHCARE, INC.	+17.28%	85.55B
CVS HEALTH CORPORATION	-28.17%	70.07B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+6.76%	28.95B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-7.30%	17.51B
FRESENIUS SE & CO. KGAA	+2.14%	17.39B
QUEST DIAGNOSTICS INCORPORATED	+1.86%	15.38B
REDE D'OR SÃO LUIZ S.A.	+6.85%	13.4B
NATERA, INC.	+65.57%	12.93B
FRESENIUS MEDICAL CARE AG	+6.64%	12.77B

Other Healthcare Facilities & Services